Nyxoah to Participate in the Jefferies Global Healthcare Conference

Company Overview - Nyxoah is a medical technology company focused on developing and commercializing innovative solutions for treating Obstructive Sleep Apnea (OSA) [3] - The company's lead product is the Genio® system, which is a patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy for OSA [3] Recent Developments - Nyxoah will participate in the Jefferies Global Healthcare Conference on June 5-6, 2024, in New York [1] - CEO Olivier Taelman will deliver a corporate presentation on June 5, 2024, at 7:30 am ET, with a webcast available on the company's Investor Relations website [2] - The company will also hold one-on-one meetings with institutional investors during the conference [2] Product Milestones - The Genio® system received its European CE Mark in 2019 following the successful completion of the BLAST OSA study [4] - Nyxoah completed IPOs on Euronext Brussels in September 2020 and NASDAQ in July 2021 [4] - The company received CE mark approval for expanding therapeutic indications to Complete Concentric Collapse (CCC) patients after positive outcomes from the BETTER SLEEP study [4] - Currently, Nyxoah is conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval [4]